Clarifying the Role of Incretin-Based Therapies in the Treatment of Type 2 Diabetes Mellitus (Q37888159)

24 August 2017

1 reference

title

Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus (English)

1 reference

24 August 2017

Clarifying the Role of Incretin-Based Therapies in the Treatment of Type 2 Diabetes Mellitus (English)

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

4 December 2024

0 references

R. Keith Campbell

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21665040

4 December 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21665040

4 December 2024

publication date

1 May 2011

1 reference

24 August 2017

May 2011

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21665040

full work available at URL

4 December 2024

https://api.elsevier.com/content/article/PII:S0149291811001986?httpAccept=text/xml

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

https://api.elsevier.com/content/article/PII:S0149291811001986?httpAccept=text/plain

4 December 2024

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

4 December 2024

published in

Clinical Therapeutics

1 reference

24 August 2017

1 reference

24 August 2017

1 reference

24 August 2017

page(s)

511-527

1 reference

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Projecting the future diabetes population size and related costs for the U.S.

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006.

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Mortality in people with Type 2 diabetes in the UK

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004.

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Metabolic and lifestyle predictors of ischemic heart disease and all-cause mortality among normal weight, overweight, and obese men: a 16-year follow-up in the Copenhagen Male Study

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Impact of long-term complications on quality of life in patients with type 2 diabetes not using insulin

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Illness representations and coping as predictors of emotional well-being in adolescents with type 1 diabetes

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Assessing diabetes patients' healthcare needs

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Counseling patients with type 2 diabetes and insulin resistance in the outpatient setting

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Individual patient education for people with type 2 diabetes mellitus

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

The direct medical cost of type 2 diabetes

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Economic costs of diabetes in the U.S. In 2007.

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

National trends in treatment of type 2 diabetes mellitus, 1994-2007

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

More choices than ever before: emerging therapies for type 2 diabetes

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

beta-cell failure in diabetes and preservation by clinical treatment

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Incretins, insulin secretion and Type 2 diabetes mellitus

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

International Union of Pharmacology. XXXV. The glucagon receptor family

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

The incretin system and its role in type 2 diabetes mellitus

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

The structure and function of CD26 in the T-cell immune response

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Incretin-based therapies in type 2 diabetes mellitus

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

The impact of medication regimen factors on adherence to chronic treatment: a review of literature

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Liraglutide Effect and Action in Diabetes (LEAD™) trial

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

GLP-1 receptor agonists for type 2 diabetes.

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-b

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Incretin-based therapies: viewpoints on the way to consensus

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

An overview of incretin clinical trials

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension

4 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.04.015

4 December 2024

Identifiers

1 reference

24 August 2017

1 reference